Application of the cellfree plasma DNA in the diagnosis and treatment of malignancies

Abstract

ZHU Xiang, WU Hui, YUAN Ai-Hua, YANG Kun-Xing, CAO Hong-Yong. Application of the cellfree plasma DNA in the diagnosis and treatment of malignancies[J]. Journal of International Oncology, 2014, 41(3): 180-183.

References

［1］ Anker P, Stroun M. Circulating nucleic acids and evolution［J］. Expert Opin Biol Ther， 2012， 12Suppl 1:S113-117. ［2］ GonzálezMasiá JA, GarcíaOlmo D, GarcíaOlmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology［J］. Onco Targets Ther， 2013， 6:819-832. ［3］ Jung K, Fleischhacker M, Rabien A. Cellfree DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature［J］. Clin Chim Acta, 2010,411(2122):1611-1624. ［4］ Suzuki N, Kamataki A, Yamaki J, et al. Characterization of circulating DNA in healthy human plasma［J］. Clin Chim Acta, 2008,387(1-2):55-58. ［5］ Li CN, Hsu HL, Wu TL, et al. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines［J］. J Clin Lab Anal， 2003， 17(4):103-107. ［6］ Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients［J］. Expert Opin Biol Ther， 2012， 12Suppl 1:S209-215. ［7］ Skvortsova TE, Vlassov VV, Laktionov PP. Binding and penetration of methylated DNA into primary and transformed human cells［J］. Ann N Y Acad Sci， 2008， 1137:36-40. ［8］ van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?［J］. Clin Biochem, 2010, 43(1-2):26-36. ［9］ Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in nonsmall cell lung cancer［J］. Lung Cancer， 2009， 64(1):92-97. ［10］ Altimari A, Grigioni AD, Benedettini E, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer［J］. Am J Clin Pathol, 2008, 129(5):756-762. ［11］ Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors［J］. Mol Cancer， 2009, 8:105. ［12］ Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients［J］. Nat Rev Cancer， 2011， 11(6):426-437. ［13］ Zhang R, Shao F, Wu X, et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis［J］. Lung Cancer, 2010, 69(2):225-231. ［14］ Wimberger P, Roth C, Pantel K, et al. Impact of platinumbased chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients［J］. Int J Cancer， 2011， 128(11):2572-2580. ［15］ Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients［J］. Cancer Res， 2003， 63(14):3966-3968. ［16］ Holdenrieder S, Burges A, Reich O, et al. DNA integrity in plasma and serum of patients with malignant and benign diseases［J］. Ann N Y Acad Sci, 2008, 1137:162-170. ［17］ ElShazly SF, Eid MA, El-Sourogy HA, et al. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virusrelated hepatocellular carcinoma［J］. Int J Biol Markers, 2010, 25(2):79-86. ［18］ Chen Z, Feng J, Buzin CH, et al. Analysis of cancer mutation signatures in blood by a novel ultrasensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer［J］. PLoS One， 2009， 4(9):e7220. ［19］ Wade M, Li YC, Wahl GM. MDM2,MDMX and p53 in oncogenesis and cancer therapy［J］. Nat Rev Cancer, 2013, 13(2):83-96. ［20］ Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics［J］. Nat Med， 2008， 14(9):985-990. ［21］ Mirza S, Sharma G, Parshad R, et al. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients［J］. Ann Surg Oncol, 2012, 19(9):3107-3115. ［22］ Melnikov A, Scholtens D, Godwin A, et al. Differential methylation profile of ovarian cancer in tissues and plasma［J］. J Mol Diagn, 2009, 11(1):60-65. ［23］ Shah SN, Hile SE, Eckert KA. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes［J］. Cancer Res， 2010， 70(2):431-435. ［24］ Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades［J］. Neuro Oncol, 2010, 12(2):173-180. ［25］ von Knobloch R, Hegele A, Brandt H, et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis［J］. Int J Cancer, 2001, 94(1):67-72. ［26］ Duffy MJ, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers (EGTM) 2014 guidelines update［J］. Int J Cancer， 2013， In Press. ［27］ Rawnaq T, Schwarzenbach H, Schurr PG, et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence［J］. J Surg Res, 2011, 169(1):31-35. ［28］ Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cellfree DNA from plasma and serum［J］. Clin Chim Acta， 2009， 404(2):100-104. ［29］ Szpechcinski A, Struniawska R, Zaleska J, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients［J］. J Physiol Pharmacol， 2008， 59Suppl 6:675-681.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.